Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Acutus Medical's cash to debt ratio for the quarter that ended in Dec. 2024 was 0.39.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Acutus Medicalcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2024.
The historical rank and industry rank for Acutus Medical's Cash-to-Debt or its related term are showing as below:
AFIB's Cash-to-Debt is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.62 * Ranked among companies with meaningful Cash-to-Debt only.
Acutus Medical (OTCPK:AFIB) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Acutus Medical Cash-to-Debt Related Terms
Acutus Medical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Acutus Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, Acutus Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acutus Medical Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acutus Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Acutus Medical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acutus Medical (AFIB) has a Cash-to-Debt of 0.39 as of Dec. 2024.
Is Acutus Medical's Cash-to-Debt too high?
Acutus Medical's current Cash-to-Debt is 0.39. The Medical Devices & Instruments industry median Cash-to-Debt is 1.62. Acutus Medical's value of 0.39 is 75.9% below this industry median.
How does Acutus Medical's Cash-to-Debt compare to DHAI and ABT?
Acutus Medical's Cash-to-Debt of 0.39 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash-to-Debt is 1.62. Acutus Medical's value of 0.39 is 75.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.62, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acutus Medical's current Cash-to-Debt of 0.39 is 75.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acutus Medical's current Cash-to-Debt is 0.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acutus Medical stock overvalued right now?
Acutus Medical (AFIB) has a current Cash-to-Debt of 0.39. The current Cash-to-Debt is 0.39 and 75.9% below the Medical Devices & Instruments industry median of 1.62. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Acutus Medical (AFIB), the current Cash-to-Debt is 0.39 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping, and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products world-wide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Outside the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AFIB has been successfully added to your 
